Covance Announces Pioneering Agreement with Leading Pharmaceutical Company for Worldwide Portfolio-Level Clinical Trial Monitoring

Xcellerate® Monitoring sets new standard for risk-based monitoring of clinical trials PRINCETON, N.J. --(BUSINESS WIRE)--Aug. 24, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced that Covance Drug Development (Covance) has received a multi-year award from

LabCorp Furthers Leadership in Personalized Medicine in Cancer by Offering Innovative VistaSeq® Hereditary Cancer Panel

VistaSeq strategically focuses on actionable genetic mutations to identify patients with increased risk of many commonly diagnosed cancers BURLINGTON, N.C. --(BUSINESS WIRE)--Aug. 24, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today the nationwide

LabCorp Announces New Covance Leadership

Deborah Keller to succeed Joe Herring as Covance Drug Development CEO BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 28, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE:LH) today announced that Deborah Keller will succeed Joseph Herring as Chief Executive Officer of Covance Drug

Laboratory Corporation of America® Holdings Announces Record 2015 Second Quarter Results and Raises 2015 Adjusted EPS Guidance

Q2 Net revenue of $2.2 billion , up 46% over last year Q2 Diluted EPS of $1.64 ; Q2 Adjusted EPS of $2.09 , up 14% over last year Q2 Free Cash Flow of $328 million , up 106% over last year 2015 Adjusted EPS guidance raised to $7.75 - $8.00 from $7.55 - $7.90 BURLINGTON, N.C. --(BUSINESS WIRE)--Jul.

Covance Opens Fit-for-Purpose Dallas Clinical Research Unit

LabCorp patient service center to be co-located in new facility to serve local patients and enhance volunteer recruitment DALLAS --(BUSINESS WIRE)--Jul. 23, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that Covance Drug Development has relocated its

Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Jul. 1, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp Expands Access to LabCorp AccuDraw® to Support Better Patient Care

BURLINGTON, N.C. --(BUSINESS WIRE)--Jun. 4, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (LH: NYSE) today announced the expanded availability of its proprietary specimen collection and handling software, LabCorp Accu Draw ® , to all clients through its website at www.LabCorp.com

LabCorp is Scheduled to Present at the Goldman Sachs 36th Annual Global Healthcare Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Jun. 2, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced it will participate at the Goldman Sachs 36 th Annual Global Healthcare Conference. LabCorp’s presentation is planned for Tuesday, June 9, 2015 at 5:00 PM (ET) .

Sysmex and LabCorp Announce a Strategic Collaboration for Blood-Based Molecular Testing Services and Products to Support the Development of Precision Medicine in Oncology

KOBE, Japan & BURLINGTON, N.C. --(BUSINESS WIRE)--Jun. 1, 2015-- Sysmex Corporation (TSE:6869) and Laboratory Corporation of America ® Holdings (LabCorp ® ) (LH:NYSE) today announced a strategic collaboration focused on the development of blood-based molecular diagnostic tests to advance precision

LabCorp Announces Full Portfolio of Hepatitis C Virus Drug Resistance Assays

Expanded testing services enable precision medicine by providing clinicians with information to select optimal treatment and characterize treatment failure BURLINGTON, N.C. --(BUSINESS WIRE)--May 18, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced the